CytomX Therapeutics 경영진
경영진 기준 점검 3/4
CytomX Therapeutics CEO는 Sean McCarthy, Aug2011 에 임명되었습니다 의 임기는 14.75 년입니다. 총 연간 보상은 $4.74M, 14.3% 급여 및 85.7% 보너스(회사 주식 및 옵션 포함)로 구성됩니다. 는 $2.69M 가치에 해당하는 회사 주식의 0.33% 직접 소유합니다. 경영진과 이사회의 평균 재임 기간은 3.3 년과 6.3 년입니다.
핵심 정보
Sean McCarthy
최고경영자
US$4.7m
총 보수
| CEO 급여 비율 | 14.25% |
| CEO 재임 기간 | 14.8yrs |
| CEO 지분 보유율 | 0.3% |
| 경영진 평균 재임 기간 | 3.3yrs |
| 이사회 평균 재임 기간 | 6.3yrs |
최근 경영진 업데이트
Recent updates
분석 기사 • May 13
Broker Revenue Forecasts For CytomX Therapeutics, Inc. (NASDAQ:CTMX) Are Surging Higher
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders will have a reason to smile today, with the analysts making...분석 기사 • May 11
Earnings Update: CytomX Therapeutics, Inc. (NASDAQ:CTMX) Just Reported And Analysts Are Boosting Their Estimates
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) defied analyst predictions to release its first-quarter results, which were...
내러티브 업데이트 • Apr 23
CTMX: Late-Line Colorectal Cancer Data Will Drive 2026 Repricing Prospects
Analysts have lifted their average price target on CytomX Therapeutics by several dollars into the low to mid teens, citing stronger confidence in late line colorectal cancer data and updated views on the probability of approval for varsetatug masetecan and CX-2051. Analyst Commentary Bullish analysts are reworking their models after the latest Phase 1 expansion data for varsetatug masetecan in late line colorectal cancer and CX-2051 in colon cancer, with several firms lifting price targets into the low to high teens.내러티브 업데이트 • Apr 09
CTMX: Late-Line Colorectal Cancer Data Will Shape 2026 Repricing Path
Analysts have nudged the fair value estimate for CytomX Therapeutics to $13.67 from $13.44, citing a wave of higher price targets across the Street following positive Phase 1 expansion data in late line colorectal cancer and updated views on key pipeline assets. Analyst Commentary Street research has shifted meaningfully in recent days, with multiple firms raising price targets and at least one upgrade from a major bank, all keyed to the latest Phase 1 expansion data in late line colorectal cancer and updated views on CytomX Therapeutics' pipeline.내러티브 업데이트 • Mar 26
CTMX: Late-Line Colorectal Cancer Data Will Drive 2026 Repricing Thesis
Analysts have lifted their price targets on CytomX Therapeutics by several dollars per share, with the updated fair value estimate moving from $9.00 to about $13.44, citing stronger confidence in late-line colorectal cancer data and higher assumed profitability for key pipeline assets. Analyst Commentary Street research on CytomX Therapeutics has turned more constructive following updated clinical data in late-line colorectal cancer and corporate updates around key pipeline assets such as varsetatug masetecan, also referenced as Varseta-M, and CX-2051.Seeking Alpha • Mar 16
CytomX: The Probody Mask Just Slipped, And Investors Like What They See (Upgrade)
Summary CytomX Therapeutics, Inc. receives a speculative Buy upgrade following promising new mCRC data for lead asset Varseta-M (CX-2051). Varseta-M shows a clear dose response and manageable safety profile with prophylactic measures, supporting the potential for a pivotal trial in 2027. CTMX valuation is highly dependent on Varseta-M in 3L+ mCRC, with risk-adjusted NPV modeled at $894M and a fully diluted fair value estimated at $7.15 per share. Significant dilution risk exists due to funding needs, but mCRC data validates CytomX’s platform, offering optionality for pipeline expansion. Read the full article on Seeking Alpha내러티브 업데이트 • Mar 11
CTMX: 2026 Colorectal Cancer Milestones Will Support Repricing Thesis
Analyst price targets for CytomX Therapeutics have moved higher by a few dollars, with the latest $2 and $3.50 target increases reflecting reassessments of fair value, updated profit margin assumptions, and a very large future P/E multiple cited by recent Street research. Analyst Commentary Recent Street research on CytomX Therapeutics clusters around higher price targets, fresh coverage and updated profit margin assumptions, all tied to the potential implied by a very large future P/E multiple.
내러티브 업데이트 • Feb 25
CTMX: Colorectal Cancer Pipeline Milestones Will Support Future Repricing
Analysts have nudged their price targets on CytomX Therapeutics higher by a few dollars, reflecting updated assumptions around slightly firmer revenue trends, a modestly lower profit margin profile, and a higher future P/E multiple in recent research from firms such as Barclays, Guggenheim, and Piper Sandler. Analyst Commentary Bullish analysts are framing the recent price target moves as a reflection of refreshed views on CytomX Therapeutics’ ability to execute on its plan, support revenue trends, and justify a higher P/E multiple over time.내러티브 업데이트 • Feb 11
CTMX: 2026 Colorectal Cancer Milestones Will Drive Upside Repricing Potential
Analysts have lifted their price targets on CytomX Therapeutics by a few dollars, citing updated fair value assumptions to about $9.00, modest tweaks to projected revenue declines and profit margins, and a higher assumed future P/E multiple. Analyst Commentary Recent Street research on CytomX Therapeutics has centered on modestly higher price targets and updated assumptions for fair value, revenue trends, and profit margins, along with a higher assumed future P/E multiple.분석 기사 • Jan 28
What CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) 35% Share Price Gain Is Not Telling You
Despite an already strong run, CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares have been powering on, with a gain of...내러티브 업데이트 • Jan 27
CTMX: Colorectal Cancer Milestones And Index Additions Will Support Future Repricing
Narrative Update The analyst price target for CytomX Therapeutics has moved modestly higher to about US$10.00 per share, as analysts factor in slightly better profit margin expectations and a somewhat lower implied future P/E multiple following recent bullish initiation and target raises from several firms. Analyst Commentary Recent research updates point to a more constructive stance on CytomX Therapeutics, with bullish analysts assigning higher price targets and initiating coverage with a positive angle.내러티브 업데이트 • Jan 11
CTMX: Colorectal Cancer Data Will Support Stronger Confidence In Lead Program
Analysts have updated their price target on CytomX Therapeutics to US$7, with the shift tied to renewed confidence in CX-2051 after recent colorectal cancer data highlighted how challenging objective responses are in this setting and how the program still stands out to many on the Street. Analyst Commentary Bullish analysts are leaning into the idea that CX-2051 could be differentiated in colorectal cancer, especially after recent Phase 2 data from another company underscored how difficult it is to achieve objective responses in this setting.내러티브 업데이트 • Dec 20
CTMX: Colorectal Cancer Data Will Drive Stronger Confidence In Lead Pipeline
Analysts have raised their price target on CytomX Therapeutics, lifting estimated fair value from about $8.00 to roughly $9.80 per share. They cite growing confidence in the risk to benefit profile and blockbuster potential of CX 2051, supported by recent colorectal cancer data comparisons and stronger projected profit margins despite a higher discount rate.내러티브 업데이트 • Dec 06
CTMX: 2026 Colorectal Cancer Data Will Drive Upside Repricing Potential
Analysts have modestly raised their price target on CytomX Therapeutics to $7.00, citing growing confidence in the risk reward profile and the blockbuster potential of lead colorectal cancer candidate CX-2051. This follows supportive sector readthroughs and solid cash runway visibility.내러티브 업데이트 • Nov 22
CTMX: Upcoming 2026 Data Will Drive New Momentum in Colorectal Cancer
Analysts have increased their price target for CytomX Therapeutics from $6.14 to $7.07 per share, citing growing confidence in the risk-to-benefit profile and blockbuster potential of the company's lead clinical program. This adjustment is based on recent industry data and supportive coverage.분석 기사 • Nov 13
Analysts Just Shaved Their CytomX Therapeutics, Inc. (NASDAQ:CTMX) Forecasts Dramatically
Today is shaping up negative for CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders, with the analysts delivering a...내러티브 업데이트 • Nov 05
CTMX: Clinical Momentum Will Drive Shares Higher Despite Recent Safety Concerns
Analysts have modestly increased their price target on CytomX Therapeutics to $6.14 per share, citing ongoing enthusiasm for the CX-2051 program. They also point to reinforced confidence following recent clinical updates and the initiation of coverage.내러티브 업데이트 • Oct 22
Analyst Commentary Signals Renewed Optimism as CytomX Therapeutics Receives Higher Price Target
Analysts have increased their fair value price target for CytomX Therapeutics from $5.75 to $6.14 per share. This change reflects growing optimism for CX-2051's clinical potential and resilient investor sentiment despite recent safety updates.분석 기사 • Oct 18
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Soars 66% But It's A Story Of Risk Vs Reward
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders would be excited to see that the share price has had a great...분석 기사 • Aug 14
Not Many Are Piling Into CytomX Therapeutics, Inc. (NASDAQ:CTMX) Stock Yet As It Plummets 26%
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders won't be pleased to see that the share price has had a very...내러티브 업데이트 • Aug 11
Late-Stage Trials And Partnerships Will Advance Precision Medicine Despite Setbacks
CytomX Therapeutics’ consensus price target has increased notably, driven by a substantially higher expected P/E despite a decline in net profit margin, resulting in a revised fair value of $5.75 per share. What's in the News First patient dosed with CX-801 in combination with KEYTRUDA in a Phase 1 dose escalation study for metastatic melanoma.분석 기사 • Jun 18
Here's Why We Think CytomX Therapeutics (NASDAQ:CTMX) Is Well Worth Watching
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...분석 기사 • May 20
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Leap 225% Yet They're Still Not Telling The Full Story
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shareholders would be excited to see that the share price has had a great...분석 기사 • May 16
CytomX Therapeutics, Inc. Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) just released its quarterly report and things are looking bullish. Statutory...분석 기사 • Apr 05
Revenues Working Against CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Share Price Following 26% Dive
Unfortunately for some shareholders, the CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) share price has dived 26% in the...
새로운 내러티브 • Feb 09
Advancements In CX-904 And CX-2051 May Drive Future Revenue Amid Funding Uncertainties
Multiple clinical readouts in 2025 could boost shareholder value and future revenue via new drug approvals.분석 기사 • Feb 04
CytomX Therapeutics, Inc. (NASDAQ:CTMX) Looks Inexpensive After Falling 26% But Perhaps Not Attractive Enough
CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares have had a horrible month, losing 26% after a relatively good period...분석 기사 • Dec 17
CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Shares Bounce 26% But Its Business Still Trails The Industry
Those holding CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) shares would be relieved that the share price has rebounded 26...분석 기사 • Oct 26
Investors Aren't Buying CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues
With a price-to-sales (or "P/S") ratio of 0.7x CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) may be sending very bullish...Seeking Alpha • Jul 15
CytomX Therapeutics' Probody Platform: Potential And Pitfalls In Oncology Treatments
Summary CytomX Therapeutics develops innovative oncology treatments using its Probody platform, creating conditionally activated biologics that increase drug efficiency and reduce side effects. Strategic partnerships with leading companies like Amgen, Astellas, and Bristol Myers Squibb leverage CTMX's Probody platform for drug development. The pipeline includes early-stage drugs CX-904, CX-2051, and CX-801, with preclinical programs. CTMX has a short cash runway and potential dilution risks in the next few years. I ultimately rate CTMX a “hold” due to balanced positives and negatives, but I think it's worth adding to your watchlist. Read the full article on Seeking Alpha분석 기사 • Jun 15
The Market Doesn't Like What It Sees From CytomX Therapeutics, Inc.'s (NASDAQ:CTMX) Revenues Yet As Shares Tumble 30%
The CytomX Therapeutics, Inc. ( NASDAQ:CTMX ) share price has fared very poorly over the last month, falling by a...CEO 보수 분석
| 날짜 | 총 보수 | 급여 | 회사 수익 |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$62m |
| Dec 31 2025 | US$5m | US$675k | -US$20m |
| Sep 30 2025 | n/a | n/a | US$28m |
| Jun 30 2025 | n/a | n/a | US$48m |
| Mar 31 2025 | n/a | n/a | US$42m |
| Dec 31 2024 | US$2m | US$675k | US$32m |
| Sep 30 2024 | n/a | n/a | US$14m |
| Jun 30 2024 | n/a | n/a | US$11m |
| Mar 31 2024 | n/a | n/a | US$17m |
| Dec 31 2023 | US$3m | US$652k | -US$569k |
| Sep 30 2023 | n/a | n/a | -US$10m |
| Jun 30 2023 | n/a | n/a | -US$42m |
| Mar 31 2023 | n/a | n/a | -US$71m |
| Dec 31 2022 | US$3m | US$623k | -US$99m |
| Sep 30 2022 | n/a | n/a | -US$149m |
| Jun 30 2022 | n/a | n/a | -US$143m |
| Mar 31 2022 | n/a | n/a | -US$132m |
| Dec 31 2021 | US$4m | US$616k | -US$116m |
| Sep 30 2021 | n/a | n/a | -US$72m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$61m |
| Dec 31 2020 | US$3m | US$595k | -US$65m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$63m |
| Mar 31 2020 | n/a | n/a | -US$76m |
| Dec 31 2019 | US$4m | US$575k | -US$133m |
보상 대 시장: Sean의 총 보수(USD4.74M)는 US 시장에서 비슷한 규모 기업의 평균(USD3.71M) 수준입니다.
보상과 수익: Sean의 보상은 회사가 적자임에도 증가했습니다.
CEO
Sean McCarthy (58 yo)
14.8yrs
재임 기간
US$4,738,495
보수
Dr. Sean A. McCarthy, D.Phil., served as an Independent Director at OncoResponse, Inc. since August 2021 until October 2025. He has been the Chief Executive Officer of CytomX Therapeutics, Inc. since Augus...
리더십 팀
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Chairman & CEO | 14.8yrs | US$4.74m | 0.33% $ 2.7m | |
| SVP, CFO & Secretary | 3.7yrs | US$1.54m | 0.057% $ 465.8k | |
| Chief Business Officer & Senior VP | less than a year | US$2.23m | 데이터 없음 | |
| Senior VP & Chief Scientific Officer | 3.3yrs | US$1.21m | 0.076% $ 620.1k | |
| Senior VP | 8yrs | US$1.21m | 0.041% $ 338.3k | |
| Senior VP & Chief Human Resources Officer | no data | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Intellectual Property | 7.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior VP & Chief Medical Officer | 2.8yrs | US$808.35k | 0.018% $ 149.0k | |
| Senior Vice President of Quality & Product Manufacturing | 3.3yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Alliances & Program Leadership | 1.2yrs | 데이터 없음 | 데이터 없음 | |
| Senior Vice President of Regulatory Affairs | no data | 데이터 없음 | 데이터 없음 |
3.3yrs
평균 재임 기간
57.5yo
평균 나이
경험이 풍부한 관리: CTMX의 경영진은 경험이 있음으로 간주됩니다(평균 재임 3.3 년).
이사회 구성원
| 이름 | 직위 | 재임 기간 | 보수 | 지분 |
|---|---|---|---|---|
| Chairman & CEO | 14.8yrs | US$4.74m | 0.33% $ 2.7m | |
| Independent Director | 7yrs | US$137.51k | 0.0024% $ 19.3k | |
| Member of Scientific Advisory Board | 6.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | no data | 데이터 없음 | 데이터 없음 | |
| Independent Director | 5.4yrs | US$136.51k | 0% $ 0 | |
| Independent Director | 7.4yrs | US$139.51k | 0% $ 0 | |
| Lead Independent Director | 10.7yrs | US$167.51k | 0% $ 0 | |
| Independent Director | 6.1yrs | US$143.01k | 0% $ 0 | |
| Member of Scientific Advisory Board | 5.4yrs | US$8.03m | 데이터 없음 | |
| Independent Director | 4.7yrs | US$131.51k | 0% $ 0 | |
| Member of Scientific Advisory Board | 6.3yrs | 데이터 없음 | 데이터 없음 | |
| Member of Scientific Advisory Board | 3.3yrs | 데이터 없음 | 데이터 없음 |
6.3yrs
평균 재임 기간
62yo
평균 나이
경험이 풍부한 이사회: CTMX의 이사회는 경험이 있음으로 간주됩니다(평균 재임 6.3 년).
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/22 08:44 |
| 종가 | 2026/05/22 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
CytomX Therapeutics, Inc.는 19명의 분석가가 다루고 있습니다. 이 중 8명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Peter Lawson | Barclays |
| Etzer Darout | Barclays |
| Ying Huang | BofA Global Research |